----

----

| þ | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934     |
|--------|------------------------------------------------------------------------------------------|
|   |                                                                                     |
|   | For the fiscal year ended October 31, 2013                                               |
|   |                                                                                     |
|   | OR                                                                                       |
|   |                                                                                     |
|  ̈ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |

|   | Large accelerated filer |  ̈ |   | Accelerated filer         |  ̈ |
|--------|-------------------------|--------|--------|---------------------------|--------|
|   |                    |   |   |                      |   |
|   | Non-accelerated filer   |  ̈ |   | Smaller reporting company | þ |

----

----

|                                              |                                                                                                               |   | Page   |   |
|---------------------------------------------------|--------------------------------------------------------------------------------------------------------------------|--------|--------|--------|
|                                              |                                                                                                               |   |   |
| Special Note Regarding Forward Looking Statements |                                                                                                               | 3      |   |
|                                              |                                                                                                               |   |   |   |
| PART I                                            |                                                                                                               |   |   |   |
| Item 1.                                           | Business                                                                                                           |   | 4      |   |
| Item 1A.                                          | Risk Factors                                                                                                       |   | 11     |   |
| Item 1B.                                          | Unresolved Staff Comments                                                                                          |   | 11     |   |
| Item 2.                                           | Properties                                                                                                         |   | 11     |   |
| Item 3.                                           | Legal Proceedings                                                                                                  |   | 11     |   |
| Item 4.                                           | Mine Safety Disclosures                                                                                            |   | 12     |   |
|                                              |                                                                                                               |   |   |   |
| PART II                                           |                                                                                                               |   |   |   |
| Item 5.                                           | Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities |   | 12     |   |
| Item 6.                                           | Selected Financial Data                                                                                            |   | 13     |   |
| Item 7.                                           | Management’s Discussion and Analysis of Financial Condition and Results of Operations                        |   | 13     |   |
| Item 7A.                                          | Quantitative and Qualitative Disclosures about Market Risk                                                         |   | 21     |   |
| Item 8.                                           | Financial Statements and Supplementary Data                                                                        |   | 22     |   |
| Item 9.                                           | Changes In and Disagreements With Accountants on Accounting and Financial Disclosure                               |   | 23     |   |
| Item 9A.                                          | Controls and Procedures                                                                                            |   | 23     |   |
| Item 9B.                                          | Other Information                                                                                                  |   | 23     |   |
|                                              |                                                                                                               |   |   |   |
| PART III                                          |                                                                                                               |   |   |   |
| Item 10.                                          | Directors, Executive Officers and Corporate Governance                                                             |   | 24     |   |
| Item 11.                                          | Executive Compensation                                                                                             |   | 27     |   |
| Item 12.                                          | Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters                     |   | 28     |   |
| Item 13.                                          | Certain Relationships and Related Transactions, and Director Independence                                          |   | 28     |   |
| Item 14.                                          | Principal Accounting Fees and Services                                                                             |   | 29     |   |
| Item 15.                                          | Exhibits, Financial Statement Schedules                                                                            |   | 30     |   |

----

----

----

----

| 1.   | Increased mechanical strength to 170Mpa. |
|----------------|------------------------------------------|

| 2.   | Increased biological activities to accelerate bone cell substitution. |
|----------------|-----------------------------------------------------------------------|

| 3.   | Extended the degeneration period during the implant. While the PA is degenerating layer by layer, the bone cells grow and take its place. |
|----------------|-------------------------------------------------------------------------------------------------------------------------------------------|

----

| ●   | There are no similar patent registrations in China. |
|---------------------|-----------------------------------------------------|

| ●   | Our initial product, the PA Screw, has completed 100% of the required clinical trials, with a 100% success rate, and now await the formality of CFDA approval. |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ●   | We are the only company qualified and permitted to conduct clinical trials of other PA products by CFDA. |
|---------------------|----------------------------------------------------------------------------------------------------------|

| ●   | We have a timing advantage over other companies in China, which would have to go through the preclinical testing before they could even apply for a permit to conduct actual clinical trials. |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ●   | Under existing regulation structure, it will take at least 3 years for any competitor’s clinical trials to be completed, and total of 7 or more years to reach the point where we are now. |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| Competing products and prices in China (screw) |
|------------------------------------------------|
| Producer                                       |   | Origin |   | Brand |   | Price (USD/PC) |
| Arthrex                                        |   | Germany/USA |   | Arthrex |   | $554.74 |
| Conmed                                         |   | USA |   | Linvatec |   | $554.74 |
| Bionx                                          |   | Finland |   | Biofix |   | $554.74 |
| Gunze                                          |   | Japan |   | Grandfix |   | $416.06 |
| Takiron                                        |   | Japan |   | Fixsorb |   | $408.76 |
| Dikang                                         |   | China |   | PDLLA |   | $321.17 |
| ABMT                                           |   | China |   | ABMT |   | $300.00 |

| -   | There are no similar patent registrations in China. |
|---------------|-----------------------------------------------------|

| -   | We are the only company qualified and permitted to take clinical trials by CFDA. |
|---------------|---------------------------------------------------------------------------------------|

| -   | We have a timing advantage over other companies in China which would have to go through the preclinical testing for the CFDA permit on Clinical Trials. |
|---------------|---------------------------------------------------------------------------------------------------------------------------------------------------------|

| -   | Under existing regulation by CFDA, it will take at least 3-5 years to complete clinical trials for a new product similar to the Company’s PA Screw, which has finished all required clinical trials. |
|---------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| PHYSICAL COMPARISON     |
|-------------------------|
|                    |   | Metal |   | PLLA |   | ABMT’s PA devices |
| Strength                |   | Excellent |   | Weak |   | Superior to PLLA |
| Unit Cost               |   | High |   | Low |   | Lowest |
| Processability          |   | Good |   | Good |   | Good |
| Modulus of Elasticity   |   | Low: may cause infection, may cause second fracture |   | Moderate to Quite Fragile |   | Excellent |
| Self-Reinforced         |   | No |   | Yes, but degradation starts too quickly |   | Yes |
| Self-Resorbable         |   | No1 |   | Yes, but initial degradation too fast in first few weeks. Initial strength down to 10~20Mpa in 4 weeks (close to osteoporosis) |   | Yes: unchanged during first 12 weeks, hardness remains 70% min through week 20. |
| Stretchability          |   | Strong |   | 50~60 Mpa |   | 170 Mpa (min) |
| Bone Healing            |   | Bone mineral density decrease averages 18% |   | Bone mineral density decrease averages 7-10% |   | Bone mineral density decrease less than 5% |
| Implant Failure Rate    |   | High to Medium |   | Medium to Low |   | Very Low |
| Need for Repeat Surgery |   | As Required2 |   | Only if failure  (second fracture) |   | No |

|                             |   | METAL                                                                                                                                                           |   | ABMT’s PA devices                                                                                                                              |
|----------------------------------|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|------------------------------------------------------------------------------------------------------------------------------------------------------|
| Cranial Growth                   |   | ● Growth restriction                                                                                                                                      |   | ● Stimulation of growth leading to better bone healing                                                                                         |
|                             |   | ● Intracranial implant migration                                                                                                                          |   |                                                                                                                                                 |
| Accumulation of Metal in tissues |   | Yes                                                                                                                                                             |   | No                                                                                                                                                   |
| Adverse Effect                   |   | ● Many necessitate removal operation either for mechanical strength of the overall structure                                                              |   | None                                                                                                                                                 |
|                             |   | ● majority of implant failures occur at the bone-screw interface with screw pullout being the most common mechanistic cause of construct failure          |   |                                                                                                                                                 |
|                             |   | ●should the bone fail to heal, these micromotions will persist and cause the metallic screw to oscillate within the far softer surrounding bone interface |   |                                                                                                                                                 |
| Stiffness for optimal healing    |   | ● Too stiff                                                                                                                                               |   | ● Optimal stiffness/flexibility characteristics to achieve surgical fixation, while conforming to the softer, more pliable bone of the patient |
|                             |   | ● Stress shielding can result in bone atrophy and degradation                                                                                             |   |                                                                                                                                                 |
| Other Effects                    |   | ● Implant palpability                                                                                                                                     |   | ● No long-term palpability                                                                                                                     |
|                             |   | ● Temperature sensitivity                                                                                                                                 |   | ● No temperature sensitivity                                                                                                                   |
|                             |   | ● Occasionally visibility                                                                                                                                 |   | ● Predictable degradation                                                                                                                      |
|                             |   | ● Could cause trauma in the event of mechanical failure                                                                                                   |   | ● Reduced patient trauma                                                                                                                       |
|                             |   | ● Imaging and radiotherapy interference                                                                                                                   |   | ● No imaging and radiotherapy interference                                                                                                     |
|                             |   | ● Potential for cross contamination                                                                                                                  |   | ● No second surgery required                                                                                                                   |
| Cost of product                  |   | Cost to hospital: $400-$2200                                                                                                                                    |   | Cost to hospital: $300                                                                                                                               |

----

|  Title: High molecular human body embedding article and its preparing process product and use |
|---------------------------------------------------------------------------------------------------------|
|  Application Number:                                                                               |  97119073 |  Application Date: |  1997.10.22 |
|  Publication Number:                                                                               |  1214939 |  Publication Date: |  1999.04.28 |
|  Approval Pub. Date:                                                                               |   |  Granted Pub. Date: |  2002.08.14 |
|  International Classification:                                                                     |  A61F2/02,A61L27/00,C08L33/00 |
|  Applicant(s) Name:                                                                                |  Liu Jianyu |
|  Address:                                                                                          |  518111 |
|  Inventor(s) Name:                                                                                 |   |
|  Attorney & Agent:                                                                             |  Li Zhi Ning |

----

----

| Fiscal Quarter                            |   | High Bid |   |   | Low Bid |   |
|-------------------------------------------|--------|----------|--------|--------|---------|--------|
| 2013                                      |   |     |   |   |    |   |
| Fourth Quarter 08-01-13 to 10-31-13  |   | $        | 0.70   |   |    | $      | 0.71 |   |
| Third Quarter 05-01-13 to 07-31-13   |   | $        | 1.00   |   |    | $      | 0.70 |   |
| Second Quarter 02-01-13 to 04-30-13  |   | $        | 1.62   |   |    | $      | 1.00 |   |
| First Quarter 11-01-12 to 01-31-13   |   | $        | 3.89   |   |    | $      | 1.02 |   |
| Fiscal Quarter                            |   | High Bid |   |   | Low Bid |   |
|-------------------------------------------|--------|----------|--------|--------|---------|--------|
| 2012                                      |   |     |   |   |    |   |
| Fourth Quarter 08-01-12 to 10-31-12  |   | $        | 4.00   |   |    | $      | 0.28 |   |
| Third Quarter 05-01-12 to 07-31-12   |   | $        | 8.00   |   |    | $      | 1.50 |   |
| Second Quarter 02-01-12 to 04-30-12  |   | $        | 3.50   |   |    | $      | 0.20 |   |
| First Quarter 11-01-11 to 01-31-12   |   | $        | 1.25   |   |    | $      | 0.20 |   |

----

| 1.  | The Company's lack of funds in new R&D, especially in clinical testing; |
|----------|-----------------------------------------------------------------------------|

| 2.  | The Company's lack of funds in new equipment and the utilization of the production process after CFDA approval; |
|----------|-----------------------------------------------------------------------------------------------------------------|

| 3.  | The Company may need to seek funding through such vehicles as convertible notes and warrants, private placements, and/or convertible debentures; |
|----------|--------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.  | The Company needs funding for marketing and network build-up; |
|----------|---------------------------------------------------------------|

| 5.  | The Company plans to seek approval for clinical testing and marketing on a worldwide basis, including US FDA approval for testing and marketing in the United States of America, and there is no guarantee that we will obtain any such approval; |
|----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 6.  | While the Company currently holds a patent originating in China, the patent does not protect our intellectual property in the United States, and the company is unsure of the validity of the patent in other countries. However, specific trade secrets are involved in the manufacturing of our product to help protect our technologies, and reverse engineering is unlikely for our types of products and technologies. Additionally, all machinery used to manufacture our products is protected by Chinese patents. |
|----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | 1.  A notably reduced need for a secondary surgery to remove implant due to post-operative complications, therefore avoiding unnecessary risk and expense on all patient care; |
|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 2.  Enhancing the performance of the materials by manufacturing them to be easily fitted to each patient, forming an exact fit; |
|--------|--------------------------------------------------------------------------------------------------------------------------------------|

|   | 3.  Improving the biological activity of materials. Clinical trial results have shown that as PA implants degrade, they promote a progressive shift of load to the new bone creating micro-motion and thereby avoiding bone atrophy due to 'stress shielding'; |
|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 4.  Reducing the chance of post-operative infection; |
|--------|-----------------------------------------------------------|

|   | 5.  Effectively controlling the degeneration speed, so that there will be no complications in treating repeat injuries; |
|--------|------------------------------------------------------------------------------------------------------------------------------|

|   | 6.  Ease of post-operative care i.e. no distortion during x-ray imaging; |
|--------|-------------------------------------------------------------------------------|

|   | 7.  Simple and cost-effective to manufacture. |
|--------|----------------------------------------------------|

----

----

|          | Output Quantity (Max.) |    | Price at ex-factory (US$) |   |   | Total Turnover (US$) |       |
|-----------------|------------------------|---------|---------------------------|--------|--------|----------------------|------------|
| PA Screw        | 100,000                | (piece) |                      |   | 180    |                 |       |   | 18,000,000 |   |
| PA Binding Wire | 240,000                | (pack)  |                      |   | 50     |                 |       |   | 12,000,000 |   |
|          |                 |    |  Total:            |   |   |                 | 30,000,000 |   |

----

|                                                                                        |   | October 2013 |   |   | October 2012 |   |   | Increase / (Decrease) |   |
|---------------------------------------------------------------------------------------------|--------|--------------|--------|--------|--------------|--------|--------|-----------------------|--------|
| Total No. of Hospitals                                                                      |   |         | 24,317 |   |         |   | 22,662 |                  |   |   | 1,655 |   |
|        Public Hospital                                   |   |         | 13,440 |   |         |   | 13,348 |                  |   |   | 92 |   |
|        Private Hospital                                  |   |         | 10,877 |   |         |   | 9,314  |                  |   |   | 1,563 |   |
|   Hospital Rating                                                                 |   |         |   |   |         |   |   |                  |   |   |   |   |
|            AAA                       |   |         | 1,728  |   |         |   | 1,471  |                  |   |   | 257 |   |
|              AA            |   |         | 6,667  |   |         |   | 6,550  |                  |   |   | 117 |   |
|                A |   |         | 6,344  |   |         |   | 5,882  |                  |   |   | 462 |   |

----

----

----

----

----

----

|                                                         |   | Pages    |
|--------------------------------------------------------------|--------|----------|
|                                                         |   |     |
| Reports of Independent Registered Public Accounting Firm     |   | F-1      |
|                                                         |   |     |
| Consolidated Balance Sheets                                  |   | F-2      |
|                                                         |   |     |
| Consolidated Statements of Operations and Comprehensive Loss |   | F-3      |
|                                                         |   |     |
| Consolidated Statements of Stockholders’ Deficit       |   | F-4      |
|                                                         |   |     |
| Consolidated Statements of Cash Flows                   |   | F-5      |
|                                                         |   |     |
| Notes to Consolidated Financial Statements                   |   | F6 - F12 |

----

----

|                                                                            |   |        |       |   |        |   |
|---------------------------------------------------------------------------------|--------|-------------|------------|--------|-------------|--------|
|                                                                            |   | October 31, |       |   | October 31, |   |
|                                                                            |   | 2013        |       |   | 2012        |   |
| ASSETS                                                                          |   |        |       |   |        |   |
|                                                                            |   |        |       |   |        |   |
| CURRENT ASSETS                                                                  |   |        |       |   |        |   |
|     Cash and cash equivalents                               |   | $           | 48,380     |   |        | $      | 49,092 |   |
|     Other receivables and prepaid expenses                  |   |        | 21,105     |   |        |   | 21,637 |   |
|        Total Current Assets                  |   |        | 69,485     |   |        |   | 70,729 |   |
|                                                                            |   |        |       |   |        |   |   |   |
| PROPERTY AND EQUIPMENT, NET                                                     |   |        | 126,568    |   |        |   | 141,613 |   |
| DEPOSIT FOR PURCHASE OF PROPERTY AND EQUIPMENT                                  |   |        | 1,140      |   |        |   | 1,670 |   |
|                                                                            |   |        |       |   |        |   |   |   |
| TOTAL ASSETS                                                                    |   | $           | 197,193    |   |        | $      | 214,012 |   |
|                                                                            |   |        |       |   |        |   |   |   |
| LIABILITIES AND STOCKHOLDERS' DEFICIT                                           |   |        |       |   |        |   |   |   |
|                                                                            |   |        |       |   |        |   |   |   |
| CURRENT LIABILITIES                                                             |   |        |       |   |        |   |   |   |
|     Other payables and accrued expenses                     |   | $           | 59,237     |   |        | $      | 38,208 |   |
|     Due to directors                                        |   |        | 455,574    |   |        |   | 507,395 |   |
|     Due to a stockholder                                    |   |        | 349,911    |   |        |   | 267,819 |   |
|     Due to related parties                                  |   |        | 2,266,916  |   |        |   | 1,626,785 |   |
|        Total Current Liabilities             |   |        | 3,131,638  |   |        |   | 2,440,207 |   |
|                                                                            |   |        |       |   |        |   |   |   |
| COMMITMENTS AND CONTINGENCIES                                                   |   |        | -          |   |        |   | - |   |
|                                                                            |   |        |       |   |        |   |   |   |
| STOCKHOLDERS' DEFICIT                                                           |   |        |       |   |        |   |   |   |
|     Common stock, $0.00001 par value, 100,000,000 shares    |   |        |       |   |        |   |   |   |
|     authorized, 56,874,850 and 56,574,850 shares issued and      |   |        |       |   |        |   |   |   |
|     outstanding as of October 31, 2013 and October 31, 2012 |   |        | 569        |   |        |   | 566 |   |
|     Additional paid-in capital                              |   |        | 1,907,889  |   |        |   | 1,671,956 |   |
|     Deferred stock compensation                             |   |        | -          |   |        |   | (1,667 | ) |
|     Accumulated deficit during development stage            |   |        | (4,572,351 | )      |        |   | (3,682,008 | ) |
|     Accumulated other comprehensive loss                    |   |        | (270,552   | )      |        |   | (215,042 | ) |
|        Total Stockholders' Deficit           |   |        | (2,934,445 | )      |        |   | (2,226,195 | ) |
|                                                                            |   |        |       |   |        |   |   |   |
| TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT                                     |   | $           | 197,193    |   |        | $      | 214,012 |   |

----

|                                                          |   |                        |       |   |                                              |   |
|---------------------------------------------------------------|--------|-----------------------------|------------|--------|---------------------------------------------------|--------|
|                                                          |   | Year ended October 31, |       |   | September 25, 2002 (inception) throughOctober 31, |   |
|                                                          |   | 2013                        |       |   | 2012                                              |   |   | 2013 |   |
| OPERATING EXPENSES                                            |   |                        |       |   |                                              |   |   |   |   |
| General and administrative expenses                           |   | $                           | 661,794    |   |                                              | $      | 496,530 |   |   | $ | 3,749,499 |   |
| Depreciation                                                  |   |                        | 26,201     |   |                                              |   | 23,324 |   |   |   | 316,835 |   |
| Research and development                                      |   |                        | 30,749     |   |                                              |   | 117,916 |   |   |   | 287,432 |   |
| Total Operating Expenses                                      |   |                        | 718,744    |   |                                              |   | 637,770 |   |   |   | 4,353,766 |   |
|                                                          |   |                        |       |   |                                              |   |   |   |   |   |   |   |
| LOSS FROM OPERATIONS                                          |   |                        | (718,744   | )      |                                              |   | (637,770 | ) |   |   | (4,353,766 | ) |
|                                                          |   |                        |       |   |                                              |   |   |   |   |   |   |   |
| OTHER EXPENSES                                                |   |                        |       |   |                                              |   |   |   |   |   |   |   |
| Government grants                                             |   |                        | -          |   |                                              |   | - |   |   |   | 244,479 |   |
| Interest income                                               |   |                        | 70         |   |                                              |   | 118 |   |   |   | 1,883 |   |
| Interest paid to a stockholder and related parties            |   |                        | (137,502   | )      |                                              |   | (95,588 | ) |   |   | (394,538 | ) |
| Imputed interest                                              |   |                        | (22,936    | )      |                                              |   | (25,347 | ) |   |   | (252,427 | ) |
| Other, net                                                    |   |                        | (11,231    | )      |                                              |   | 62 |   |   |   | (35,187 | ) |
| Total Other Expenses, net                                     |   |                        | (171,599   | )      |                                              |   | (120,755 | ) |   |   | (435,790 | ) |
|                                                          |   |                        |       |   |                                              |   |   |   |   |   |   |   |
| LOSS FROM OPERATIONS BEFORE TAXES                             |   |                        | (890,343   | )      |                                              |   | (758,525 | ) |   |   | (4,789,556 | ) |
| Income tax expense                                            |   |                        | -          |   |                                              |   | - |   |   |   | - |   |
| NET LOSS                                                      |   |                        | (890,343   | )      |                                              |   | (758,525 | ) |   |   | (4,789,556 | ) |
| Net loss attributable to non-controlling interests            |   |                        | -          |   |                                              |   | - |   |   |   | 217,205 |   |
| NET LOSS ATTRIBUTABLE TO ABMT COMMON STOCKHOLDERS             |   |                        | (890,343   | )      |                                              |   | (758,525 | ) |   |   | (4,572,351 | ) |
|                                                          |   |                        |       |   |                                              |   |   |   |   |   |   |   |
| OTHER COMPREHENSIVE LOSS                                      |   |                        |       |   |                                              |   |   |   |   |   |   |   |
| Foreign currency translation loss                             |   |                        | (55,510    | )      |                                              |   | (36,081 | ) |   |   | (270,552 | ) |
| COMPREHENSIVE LOSS ATTRIBUTABLE TO ABMT COMMON STOCKHOLDERS   |   | $                           | (945,853   | )      |                                              | $      | (794,606 | ) |   | $ | (4,842,903 | ) |
|                                                          |   |                        |       |   |                                              |   |   |   |   |   |   |   |
|                                                          |   |                        |       |   |                                              |   |   |   |   |   |   |   |
| Net loss per share                                            |   |                        |       |   |                                              |   |   |   |   |   |   |   |
| - basic and diluted                                           |   | $                           | (0.02      | )      |                                              | $      | (0.01 | ) |   |   |   |   |
|                                                          |   |                        |       |   |                                              |   |   |   |   |   |   |   |
| Weighted average number of shares outstanding during the year |   |                        |       |   |                                              |   |   |   |   |   |   |   |
| - basic and diluted                                           |   |                        | 56,578,138 |   |                                              |   | 56,564,741 |   |   |   |   |   |

----

|                                                                |   |         |       |   |                |   |    |      |   |   |       |   |   |          |    |   |                            |   |     |             |   |   |        |   |   |          |          |
|---------------------------------------------------------------------|--------|--------------|------------|--------|---------------------|--------|---------|-----------|--------|--------|------------|--------|--------|---------------|---------|--------|---------------------------------|--------|----------|------------------|--------|--------|-------------|--------|--------|---------------|---------------|
|                                                                |   | Common stock |       |   | Shares to be issued |   |    | Stock     |   |   | Additional |   |   | Deferred      |    |   | Accumulated deficit during |   |     | Accumulatedother |   |   | Non-        |   |   |          |          |
|                                                                |   | Number       |       |   |                |   |    | Number    |   |   |       |   |   | subscriptions |    |   | paid-in                         |   |     | stock            |   |   | development |   |   | comprehensive |          |   | controlling |   |   |   |   |
|                                                                |   | of shares    |       |   | Amount              |   |    | of shares |   |   | Amount     |   |   | receivable    |    |   | capital                         |   |     | compensation     |   |   | stage       |   |   | loss          |          |   | interests |   |   | Total |   |
|                                                                |   |         |       |   |                |   |    |      |   |   |       |   |   |          |    |   |                            |   |     |             |   |   |        |   |   |          |          |   |   |   |   |   |   |
| Stock issued to founders for cash                                   |   |         | 50,510,000 |   |                | $      | 505     |      |   |   | -          |   |   | $             | -       |   |                            | $      | -        |             |   | $      | 275,002     |   |   | $             | -             |   |   | $ | - |   |   | $ | - |   |   | $ | 217,205 |   |   | $ | 492,712 |   |
|                                                                |   |         |       |   |                |   |    |      |   |   |       |   |   |          |    |   |                            |   |     |             |   |   |        |   |   |          |          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Net loss for the period                                             |   |         | -     |   |                |   | -  |      |   |   | -     |   |   |          | -  |   |                            |   | -   |             |   |   | -      |   |   |          | -   |   |   |   | (40,343 | ) |   |   | - |   |   |   | (17,290 | ) |   |   | (57,633 | ) |
|                                                                |   |         |       |   |                |   |    |      |   |   |       |   |   |          |    |   |                            |   |     |             |   |   |        |   |   |          |          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Foreign currency translation loss                                   |   |         | -     |   |                |   | -  |      |   |   | -     |   |   |          | -  |   |                            |   | -   |             |   |   | -      |   |   |          | -        |   |   |   | - |   |   |   | (225 | ) |   |   | 10 |   |   |   | (215 | ) |
|                                                                |   |         |       |   |                |   |    |      |   |   |       |   |   |          |    |   |                            |   |     |             |   |   |        |   |   |          |          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Balance at December 31, 2003                                        |   |         | 50,510,000 |   |                | $      | 505     |      |   |   | -          |   |   | $             | -       |   |                            | $      | -        |             |   | $      | 275,002     |   |   | $             | -             |   |   | $ | (40,343 | ) |   | $ | (225 | ) |   | $ | 199,925 |   |   | $ | 434,864 |   |
|                                                                |   |         |       |   |                |   |    |      |   |   |       |   |   |          |    |   |                            |   |     |             |   |   |        |   |   |          |          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Net loss for the year                                               |   |         | -     |   |                |   | -  |      |   |   | -     |   |   |          | -  |   |                            |   | -   |             |   |   | -      |   |   |          | -        |   |   |   | (65,960 | ) |   |   | - |   |   |   | (28,269 | ) |   |   | (94,229 | ) |
|                                                                |   |         |       |   |                |   |    |      |   |   |       |   |   |          |    |   |                            |   |     |             |   |   |        |   |   |          |          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Foreign currency translation loss                                   |   |         | -     |   |                |   | -  |      |   |   | -     |   |   |          | -  |   |                            |   | -   |             |   |   | -      |   |   |          | -        |   |   |   | - |   |   |   | (357 | ) |   |   | 2 |   |   |   | (355 | ) |
|                                                                |   |         |       |   |                |   |    |      |   |   |       |   |   |          |    |   |                            |   |     |             |   |   |        |   |   |          |          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Balance at December 31, 2004                                        |   |         | 50,510,000 |   |                | $      | 505     |      |   |   | -          |   |   | $             | -       |   |                            | $      | -        |             |   | $      | 275,002     |   |   | $             | -             |   |   | $ | (106,303 | ) |   | $ | (582 | ) |   | $ | 171,658 |   |   | $ | 340,280 |   |
|                                                                |   |         |       |   |                |   |    |      |   |   |       |   |   |          |    |   |                            |   |     |             |   |   |        |   |   |          |          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Imputed Interest on advances from a stockholder and related company |   |         | -     |   |                |   | -  |      |   |   | -     |   |   |          | -  |   |                            |   | -   |             |   |   | 23,103      |   |   |          | -        |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 23,103 |   |
|                                                                |   |         |       |   |                |   |    |      |   |   |       |   |   |          |    |   |                            |   |     |             |   |   |        |   |   |          |          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Net loss for the year                                               |   |         | -     |   |                |   | -  |      |   |   | -     |   |   |          | -  |   |                            |   | -   |             |   |   | -      |   |   |          | -        |   |   |   | (357,863 | ) |   |   | - |   |   |   | (153,370 | ) |   |   | (511,233 | ) |
|                                                                |   |         |       |   |                |   |    |      |   |   |       |   |   |          |    |   |                            |   |     |             |   |   |        |   |   |          |          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Foreign currency translation loss                                   |   |         | -     |   |                |   | -  |      |   |   | -     |   |   |          | -  |   |                            |   | -   |             |   |   | -      |   |   |          | -        |   |   |   | - |   |   |   | (12,290 | ) |   |   | 2,064 |   |   |   | (10,226 | ) |
|                                                                |   |         |       |   |                |   |    |      |   |   |       |   |   |          |    |   |                            |   |     |             |   |   |        |   |   |          |          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Balance at December 31, 2005                                        |   |         | 50,510,000 |   |                | $      | 505     |      |   |   | -          |   |   | $             | -       |   |                            | $      | -        |             |   | $      | 298,105     |   |   | $             | -             |   |   | $ | (464,166 | ) |   | $ | (12,872 | ) |   | $ | 20,352 |   |   | $ | (158,076 | ) |
|                                                                |   |         |       |   |                |   |    |      |   |   |       |   |   |          |    |   |                            |   |     |             |   |   |        |   |   |          |          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Imputed Interest on advances from a stockholder and related company |   |         | -     |   |                |   | -  |      |   |   | -     |   |   |          | -  |   |                            |   | -   |             |   |   | 27,184      |   |   |          | -        |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 27,184 |   |
|                                                                |   |         |       |   |                |   |    |      |   |   |       |   |   |          |    |   |                            |   |     |             |   |   |        |   |   |          |          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Net loss for the year                                               |   |         | -     |   |                |   | -       |      |   |   | -     |   |   |          | -  |   |                            |   | -   |             |   |   | -      |   |   |          | -        |   |   |   | (172,738 | ) |   |   | - |   |   |   | (18,276 | ) |   |   | (191,014 | ) |
|                                                                |   |         |       |   |                |   |    |      |   |   |       |   |   |          |    |   |                            |   |     |             |   |   |        |   |   |          |          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Foreign currency translation loss                                   |   |         | -     |   |                |   | -  |      |   |   | -     |   |   |          | -  |   |                            |   | -   |             |   |   | -      |   |   |          | -        |   |   |   | - |   |   |   | (6,084 | ) |   |   | (2,076 | ) |   |   | (8,160 | ) |
|                                                                |   |         |       |   |                |   |    |      |   |   |       |   |   |          |    |   |                            |   |     |             |   |   |        |   |   |          |          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Balance at December 31, 2006                                        |   |         | 50,510,000 |   |                | $      | 505     |      |   |   | -          |   |   | $             | -       |   |                            | $      | -        |             |   | $      | 325,289     |   |   | $             | -             |   |   | $ | (636,904 | ) |   | $ | (18,956 | ) |   | $ | - |   |   | $ | (330,066 | ) |
|                                                                |   |         |       |   |                |   |    |      |   |   |       |   |   |          |    |   |                            |   |     |             |   |   |        |   |   |          |          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Imputed Interest on advances from a stockholder and related party   |   |         | -     |   |                |   | -  |      |   |   | -     |   |   |          | -  |   |                            |   | -   |             |   |   | 39,021      |   |   |          | -        |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 39,021 |   |
|                                                                |   |         |       |   |                |   |    |      |   |   |       |   |   |          |    |   |                            |   |     |             |   |   |        |   |   |          |          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Net loss for the year                                               |   |         | -     |   |                |   | -  |      |   |   | -     |   |   |          | -  |   |                            |   | -   |             |   |   | -      |   |   |          | -        |   |   |   | (196,871 | ) |   |   | - |   |   |   | - |   |   |   | (196,871 | ) |
|                                                                |   |         |       |   |                |   |    |      |   |   |       |   |   |          |    |   |                            |   |     |             |   |   |        |   |   |          |          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Foreign currency translation loss                                   |   |         | -     |   |                |   | -  |      |   |   | -     |   |   |          | -  |   |                            |   | -   |             |   |   | -      |   |   |          | -        |   |   |   | - |   |   |   | (27,401 | ) |   |   | - |   |   |   | (27,401 | ) |
|                                                                |   |         |       |   |                |   |    |      |   |   |       |   |   |          |    |   |                            |   |     |             |   |   |        |   |   |          |          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Balance at December 31, 2007                                        |   |         | 50,510,000 |   |                | $      | 505     |      |   |   | -          |   |   | $             | -       |   |                            | $      | -        |             |   | $      | 364,310     |   |   | $             | -             |   |   | $ | (833,775 | ) |   | $ | (46,357 | ) |   | $ | - |   |   | $ | (515,317 | ) |
|                                                                |   |         |       |   |                |   |    |      |   |   |       |   |   |          |    |   |                            |   |     |             |   |   |        |   |   |          |          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Imputed Interest on advances from a stockholder and related company |   |         | -     |   |                |   | -  |      |   |   | -     |   |   |          | -  |   |                            |   | -   |             |   |   | 27,764      |   |   |          | -        |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 27,764 |   |
|                                                                |   |         |       |   |                |   |    |      |   |   |       |   |   |          |    |   |                            |   |     |             |   |   |        |   |   |          |          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Net loss for the year                                               |   |         | -     |   |                |   | -  |      |   |   | -     |   |   |          | -  |   |                            |   | -   |             |   |   | -      |   |   |          | -        |   |   |   | (227,038 | ) |   |   | - |   |   |   | - |   |   |   | (227,038 | ) |
|                                                                |   |         |       |   |                |   |    |      |   |   |       |   |   |          |    |   |                            |   |     |             |   |   |        |   |   |          |          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Foreign currency translation loss                                   |   |         | -     |   |                |   | -  |      |   |   | -     |   |   |          | -  |   |                            |   | -   |             |   |   | -      |   |   |          | -        |   |   |   | - |   |   |   | (35,833 | ) |   |   | - |   |   |   | (35,833 | ) |
|                                                                |   |         |       |   |                |   |    |      |   |   |       |   |   |          |    |   |                            |   |     |             |   |   |        |   |   |          |          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Balance at October 31,2008                                          |   |         | 50,510,000 |   |                | $      | 505     |      |   |   | -          |   |   | $             | -       |   |                            | $      | -        |             |   | $      | 392,074     |   |   | $             | -             |   |   | $ | (1,060,813 | ) |   | $ | (82,190 | ) |   | $ | - |   |   | $ | (750,424 | ) |
|                                                                |   |         |       |   |                |   |    |      |   |   |       |   |   |          |    |   |                            |   |     |             |   |   |        |   |   |          |          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Recapitalization                                                    |   |         | 5,104,000  |   |                |   | 51      |      |   |   | -          |   |   |          | -       |   |                            |   | -        |             |   |   | (51         | )      |   |          | -             |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |
|                                                                |   |         |       |   |                |   |    |      |   |   |       |   |   |          |    |   |                            |   |     |             |   |   |        |   |   |          |          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Stock issued for services ($3.05 per share)                         |   |         | 100,000    |   |                |   | 1       |      |   |   | -     |   |   |          | -       |   |                            |   | -        |             |   |   | 304,999     |   |   |          | (292,292      | ) |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 12,708 |   |
|                                                                |   |         |       |   |                |   |    |      |   |   |       |   |   |          |    |   |                            |   |     |             |   |   |        |   |   |          |          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Stock issued for cash in private placement                          |   |         |       |   |                |   |    |      |   |   |       |   |   |          |    |   |                            |   |     |             |   |   |        |   |   |          |          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| ($1.15 per share)                                                   |   |         | 5,000      |   |                |   | -       |      |   |   | -     |   |   |          | -       |   |                            |   | -        |             |   |   | 5,750       |   |   |          | -             |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 5,750 |   |
|                                                                |   |         |       |   |                |   |    |      |   |   |       |   |   |          |    |   |                            |   |     |             |   |   |        |   |   |          |          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Stock issued for cash in private placement                          |   |         |       |   |                |   |    |      |   |   |       |   |   |          |    |   |                            |   |     |             |   |   |        |   |   |          |          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| ($1.15 per share)                                                   |   |         | 2,000      |   |                |   | -       |      |   |   | -     |   |   |          | -       |   |                            |   | -        |             |   |   | 2,300       |   |   |          | -             |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 2,300 |   |
|                                                                |   |         |       |   |                |   |    |      |   |   |       |   |   |          |    |   |                            |   |     |             |   |   |        |   |   |          |          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Contributed capital                                                 |   |         | -          |   |                |   | -       |      |   |   | -     |   |   |          | -       |   |                            |   | -        |             |   |   | 26,950      |   |   |          | -             |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 26,950 |   |
|                                                                |   |         |       |   |                |   |    |      |   |   |       |   |   |          |    |   |                            |   |     |             |   |   |        |   |   |          |          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Distributed to the stockholders                                     |   |         | -     |   |                |   | -  |      |   |   | -     |   |   |          | -  |   |                            |   |     |             |   |   | (31,409     | )      |   |          | -             |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | (31,409 | ) |
|                                                                |   |         |       |   |                |   |    |      |   |   |       |   |   |          |    |   |                            |   |     |             |   |   |        |   |   |          |          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Imputed Interest on advances from a stockholder and related company |   |         | -     |   |                |   | -  |      |   |   | -     |   |   |          | -  |   |                            |   | -   |             |   |   | 31,656      |   |   |          | -        |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 31,656 |   |
|                                                                |   |         |       |   |                |   |    |      |   |   |       |   |   |          |    |   |                            |   |     |             |   |   |        |   |   |          |          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Net loss for the year                                               |   |         | -     |   |                |   | -  |      |   |   | -     |   |   |          | -  |   |                            |   | -   |             |   |   | -      |   |   |          | -        |   |   |   | (558,432 | ) |   |   | - |   |   |   | - |   |   |   | (558,432 | ) |
|                                                                |   |         |       |   |                |   |    |      |   |   |       |   |   |          |    |   |                            |   |     |             |   |   |        |   |   |          |          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Foreign currency translation loss                                   |   |         | -     |   |                |   | -  |      |   |   | -     |   |   |          | -  |   |                            |   | -   |             |   |   | -      |   |   |          | -        |   |   |   | - |   |   |   | (1,856 | ) |   |   | - |   |   |   | (1,856 | ) |
|                                                                |   |         |       |   |                |   |    |      |   |   |       |   |   |          |    |   |                            |   |     |             |   |   |        |   |   |          |          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Balance at October 31, 2009                                         |   |         | 55,721,000 |   |                | $      | 557     |      |   |   | -          |   |   | $             | -       |   |                            | $      | -        |             |   | $      | 732,269     |   |   | $             | (292,292      | ) |   | $ | (1,619,245 | ) |   | $ | (84,046 | ) |   | $ | - |   |   | $ | (1,262,757 | ) |
|                                                                |   |         |       |   |                |   |    |      |   |   |       |   |   |          |    |   |                            |   |     |             |   |   |        |   |   |          |          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Stock issued for cash in private placement                          |   |         |       |   |                |   |    |      |   |   |       |   |   |          |    |   |                            |   |     |             |   |   |        |   |   |          |          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| ($1.5 per share)                                                    |   |         | 6,667      |   |                |   | -       |      |   |   | -     |   |   |          | -       |   |                            |   | -        |             |   |   | 10,000      |   |   |          | -             |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 10,000 |   |
|                                                                |   |         |       |   |                |   |    |      |   |   |       |   |   |          |    |   |                            |   |     |             |   |   |        |   |   |          |          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Stock issued for cash in private placement                          |   |         |       |   |                |   |    |      |   |   |       |   |   |          |    |   |                            |   |     |             |   |   |        |   |   |          |          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| ($1.5 per share)                                                    |   |         | 16,667     |   |                |   | -       |      |   |   | -     |   |   |          | -       |   |                            |   | -        |             |   |   | 25,000      |   |   |          | -             |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 25,000 |   |
|                                                                |   |         |       |   |                |   |    |      |   |   |       |   |   |          |    |   |                            |   |     |             |   |   |        |   |   |          |          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Stock issued for cash in private placement                          |   |         |       |   |                |   |    |      |   |   |       |   |   |          |    |   |                            |   |     |             |   |   |        |   |   |          |          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| ($1.5 per share)                                                    |   |         | 136,833    |   |                |   | 2       |      |   |   | -     |   |   |          | -       |   |                            |   | -        |             |   |   | 205,248     |   |   |          | -             |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 205,250 |   |
|                                                                |   |         |       |   |                |   |    |      |   |   |       |   |   |          |    |   |                            |   |     |             |   |   |        |   |   |          |          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Stock issued for cash in private placement                          |   |         |       |   |                |   |    |      |   |   |       |   |   |          |    |   |                            |   |     |             |   |   |        |   |   |          |          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| ($1.0 per share)                                                    |   |         | -          |   |                |   | -       |      |   |   | 230,000    |   |   |          | 2       |   |                            |   | (230,000 | )                |   |   | 229,998     |   |   |          | -             |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |
|                                                                |   |         |       |   |                |   |    |      |   |   |       |   |   |          |    |   |                            |   |     |             |   |   |        |   |   |          |          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Stock issued for services ($1 per share)                            |   |         | 100,000    |   |                |   | 1       |      |   |   | -     |   |   |          | -       |   |                            |   | -        |             |   |   | 99,999      |   |   |          | (100,000      | ) |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |
|                                                                |   |         |       |   |                |   |    |      |   |   |       |   |   |          |    |   |                            |   |     |             |   |   |        |   |   |          |          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Stock issued for services ($1 per share)                            |   |         | 13,683     |   |                |   | -       |      |   |   | -     |   |   |          | -       |   |                            |   | -        |             |   |   | 13,683      |   |   |          | (13,683       | ) |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |
|                                                                |   |         |       |   |                |   |    |      |   |   |       |   |   |          |    |   |                            |   |     |             |   |   |        |   |   |          |          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Stock issued for services ($1 per share)                            |   |         | 150,000    |   |                |   | 2       |      |   |   | -     |   |   |          | -       |   |                            |   | -        |             |   |   | 149,998     |   |   |          | (150,000      | ) |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |
|                                                                |   |         |       |   |                |   |    |      |   |   |       |   |   |          |    |   |                            |   |     |             |   |   |        |   |   |          |          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Amortisation for stock issued for services                          |   |         | -     |   |                |   | -  |      |   |   | -          |   |   |          | -  |   |                            |   | -   |             |   |   | -           |   |   |          | 349,516       |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 349,516 |   |
|                                                                |   |         |       |   |                |   |    |      |   |   |       |   |   |          |    |   |                            |   |     |             |   |   |        |   |   |          |          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Imputed interest on advances from a stockholder and related company |   |         | -     |   |                |   | -  |      |   |   | -     |   |   |          | -  |   |                            |   | -   |             |   |   | 28,356      |   |   |          | -        |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 28,356 |   |
|                                                                |   |         |       |   |                |   |    |      |   |   |       |   |   |          |    |   |                            |   |     |             |   |   |        |   |   |          |          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Net loss for the year                                               |   |         | -     |   |                |   | -  |      |   |   | -     |   |   |          | -  |   |                            |   | -   |             |   |   | -      |   |   |          | -        |   |   |   | (816,799 | ) |   |   | - |   |   |   | - |   |   |   | (816,799 | ) |
|                                                                |   |         |       |   |                |   |    |      |   |   |       |   |   |          |    |   |                            |   |     |             |   |   |        |   |   |          |          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Foreign currency translation loss                                   |   |         | -     |   |                |   | -  |      |   |   | -     |   |   |          | -  |   |                            |   | -   |             |   |   | -      |   |   |          | -        |   |   |   | - |   |   |   | (29,063 | ) |   |   | - |   |   |   | (29,063 | ) |
|                                                                |   |         |       |   |                |   |    |      |   |   |       |   |   |          |    |   |                            |   |     |             |   |   |        |   |   |          |          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Balance at October 31, 2010                                         |   |         | 56,144,850 |   |                | $      | 562     |      |   |   | 230,000    |   |   | $             | 2       |   |                            | $      | (230,000 | )                |   | $      | 1,494,551   |   |   | $             | (206,459      | ) |   | $ | (2,436,044 | ) |   | $ | (113,109 | ) |   | $ | - |   |   | $ | (1,490,497 | ) |
|                                                                |   |         |       |   |                |   |    |      |   |   |       |   |   |          |    |   |                            |   |     |             |   |   |        |   |   |          |          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|                                                                |   |         |       |   |                |   |    |      |   |   |       |   |   |          |    |   |                            |   |     |             |   |   |        |   |   |          |          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Stock issued for cash in private placement                          |   |         |       |   |                |   |    |      |   |   |       |   |   |          |    |   |                            |   |     |             |   |   |        |   |   |          |          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| ($1 per share)                                                      |   |         | 230,000    |   |                |   | 2       |      |   |   | (230,000   | )      |   |          | (2      | )      |                            |   | 230,000  |             |   |   | -           |   |   |          | -             |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 230,000 |   |
|                                                                |   |         |       |   |                |   |    |      |   |   |       |   |   |          |    |   |                            |   |     |             |   |   |        |   |   |          |          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Stock issued for cash in private placement                          |   |         |       |   |                |   |    |      |   |   |       |   |   |          |    |   |                            |   |     |             |   |   |        |   |   |          |          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| ($1.05 per share)                                                   |   |         | 100,000    |   |                |   | 1       |      |   |   |       |   |   |          | -       |   |                            |   | -        |             |   |   | 104,999     |   |   |          | (105,000      | ) |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |
|                                                                |   |         |       |   |                |   |    |      |   |   |       |   |   |          |    |   |                            |   |     |             |   |   |        |   |   |          |          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|                                                                |   |         |       |   |                |   |    |      |   |   |       |   |   |          |    |   |                            |   |     |             |   |   |        |   |   |          |          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Imputed interest on advances from a stockholder and related company |   |         | -     |   |                |   | -  |      |   |   | -     |   |   |          | -  |   |                            |   | -   |             |   |   | 27,060      |   |   |          | -             |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 27,060 |   |
|                                                                |   |         |       |   |                |   |    |      |   |   |       |   |   |          |    |   |                            |   |     |             |   |   |        |   |   |          |          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Amortisation for stock issued for services                          |   |         | -     |   |                |   | -  |      |   |   | -     |   |   |          | -  |   |                            |   | -   |             |   |   | -           |   |   |          | 223,958       |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 223,958 |   |
|                                                                |   |         |       |   |                |   |    |      |   |   |       |   |   |          |    |   |                            |   |     |             |   |   |        |   |   |          |          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Net loss for the year                                               |   |         | -     |   |                |   | -  |      |   |   | -     |   |   |          | -  |   |                            |   | -   |             |   |   | -      |   |   |          | -        |   |   |   | (487,439 | ) |   |   | - |   |   |   | - |   |   |   | (487,439 | ) |
|                                                                |   |         |       |   |                |   |    |      |   |   |       |   |   |          |    |   |                            |   |     |             |   |   |        |   |   |          |          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Foreign currency translation loss                                   |   |         | -     |   |                |   | -  |      |   |   | -     |   |   |          | -  |   |                            |   | -   |             |   |   | -      |   |   |          | -        |   |   |   | - |   |   |   | (65,852 | ) |   |   | - |   |   |   | (65,852 | ) |
|                                                                |   |         |       |   |                |   |    |      |   |   |       |   |   |          |    |   |                            |   |     |             |   |   |        |   |   |          |          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Balance at October 31, 2011                                         |   |         | 56,474,850 |   |                | $      | 565     |      |   |   | -          |   |   | $             | -       |   |                            | $      | -        |             |   | $      | 1,626,610   |   |   | $             | (87,501       | ) |   | $ | (2,923,483 | ) |   | $ | (178,961 | ) |   | $ | - |   |   | $ | (1,562,770 | ) |
|                                                                |   |         |       |   |                |   |    |      |   |   |       |   |   |          |    |   |                            |   |     |             |   |   |        |   |   |          |          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Stock issued for services ($0.2 per share)                          |   |         | 100,000    |   |                |   | 1       |      |   |   | -     |   |   |          | -       |   |                            |   | -        |             |   |   | 19,999      |   |   |          | (20,000       | ) |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |
|                                                                |   |         |       |   |                |   |    |      |   |   |       |   |   |          |    |   |                            |   |     |             |   |   |        |   |   |          |          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Imputed interest on advances from director                          |   |         | -     |   |                |   | -  |      |   |   | -     |   |   |          | -  |   |                            |   | -   |             |   |   | 25,347      |   |   |          | -             |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 25,347 |   |
|                                                                |   |         |       |   |                |   |    |      |   |   |       |   |   |          |    |   |                            |   |     |             |   |   |        |   |   |          |          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Amortisation for stock issued for services                          |   |         | -     |   |                |   | -  |      |   |   | -     |   |   |          | -  |   |                            |   | -   |             |   |   | -           |   |   |          | 105,834       |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 105,834 |   |
|                                                                |   |         |       |   |                |   |    |      |   |   |       |   |   |          |    |   |                            |   |     |             |   |   |        |   |   |          |          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Net loss for the year                                               |   |         | -     |   |                |   | -  |      |   |   | -     |   |   |          | -  |   |                            |   | -   |             |   |   | -      |   |   |          | -        |   |   |   | (758,525 | ) |   |   | - |   |   |   | - |   |   |   | (758,525 | ) |
|                                                                |   |         |       |   |                |   |    |      |   |   |       |   |   |          |    |   |                            |   |     |             |   |   |        |   |   |          |          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Foreign currency translation loss                                   |   |         | -     |   |                |   | -  |      |   |   | -     |   |   |          | -  |   |                            |   | -   |             |   |   | -      |   |   |          | -        |   |   |   | - |   |   |   | (36,081 | ) |   |   | - |   |   |   | (36,081 | ) |
|                                                                |   |         |       |   |                |   |    |      |   |   |       |   |   |          |    |   |                            |   |     |             |   |   |        |   |   |          |          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Balance at October 31, 2012                                         |   |         | 56,574,850 |   |                | $      | 566     |      |   |   | -          |   |   | $             | -       |   |                            | $      | -        |             |   | $      | 1,671,956   |   |   | $             | (1,667        | ) |   | $ | (3,682,008 | ) |   | $ | (215,042 | ) |   | $ | - |   |   | $ | (2,226,195 | ) |
|                                                                |   |         |       |   |                |   |    |      |   |   |       |   |   |          |    |   |                            |   |     |             |   |   |        |   |   |          |          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Stock issued for services ($0.71 per share)                         |   |         | 300,000    |   |                |   | 3       |      |   |   | -     |   |   |          | -       |   |                            |   | -        |             |   |   | 212,997     |   |   |          |          |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 213,000 |   |
|                                                                |   |         |       |   |                |   |    |      |   |   |       |   |   |          |    |   |                            |   |     |             |   |   |        |   |   |          |          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Imputed interest on advances from directors                         |   |         | -     |   |                |   | -  |      |   |   | -     |   |   |          | -  |   |                            |   | -   |             |   |   | 22,936      |   |   |          | -             |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 22,936 |   |
|                                                                |   |         |       |   |                |   |    |      |   |   |       |   |   |          |    |   |                            |   |     |             |   |   |        |   |   |          |          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Amortisation for stock issued for services                          |   |         | -     |   |                |   | -  |      |   |   | -     |   |   |          | -  |   |                            |   | -   |             |   |   | -           |   |   |          | 1,667         |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 1,667 |   |
|                                                                |   |         |       |   |                |   |    |      |   |   |       |   |   |          |    |   |                            |   |     |             |   |   |        |   |   |          |          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Net loss for the year                                               |   |         | -     |   |                |   | -  |      |   |   | -     |   |   |          | -  |   |                            |   | -   |             |   |   | -      |   |   |          | -        |   |   |   | (890,343 | ) |   |   | - |   |   |   | - |   |   |   | (890,343 | ) |
|                                                                |   |         |       |   |                |   |    |      |   |   |       |   |   |          |    |   |                            |   |     |             |   |   |        |   |   |          |          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Foreign currency translation loss                                   |   |         | -     |   |                |   | -  |      |   |   | -     |   |   |          | -  |   |                            |   | -   |             |   |   | -      |   |   |          | -        |   |   |   | - |   |   |   | (55,510 | ) |   |   | - |   |   |   | (55,510 | ) |
|                                                                |   |         |       |   |                |   |    |      |   |   |       |   |   |          |    |   |                            |   |     |             |   |   |        |   |   |          |          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Balance at October 31, 2013                                         |   |         | 56,874,850 |   |                | $      | 569     |      |   |   | -          |   |   | $             | -       |   |                            | $      | -        |             |   | $      | 1,907,889   |   |   | $             | -             |   |   | $ | (4,572,351 | ) |   | $ | (270,552 | ) |   | $ | - |   |   | $ | (2,934,445 | ) |

----

|                                                                                                                    |   |        |     |   |                |   |     |               |   |
|-------------------------------------------------------------------------------------------------------------------------|--------|-------------|----------|--------|---------------------|--------|----------|--------------------|--------|
|                                                                                                                    |   |        |     |   |                |   |     | September 25, 2002 |   |
|                                                                                                                    |   | Year ended  |     |   | (inception) through |   |
|                                                                                                                    |   | October 31, |     |   | October 31,         |   |
|                                                                                                                    |   | 2013        |     |   | 2012                |   |     | 2013               |   |
| CASH FLOWS FROM OPERATING ACTIVITIES                                                                                    |   |        |     |   |                |   |     |               |   |
|     Net loss                                                                                        |   | $           | (890,343 | )      |                | $      | (758,525 | )                  |   | $ | (4,572,351 | ) |
|          Adjustments to reconcile net loss to cash used in operating activities |   |        |     |   |                |   |     |               |   |   |   |   |
|        Depreciation                                                                  |   |        | 26,201   |   |                |   | 23,324   |               |   |   | 316,835 |   |
|        Loss on disposal of property and equipment                                    |   |        | -        |   |                |   | -        |               |   |   | 11,704 |   |
|        Stock issued for services                                                     |   |        | 214,667  |   |                |   | 105,834  |               |   |   | 906,683 |   |
|        Non-controlling interests                                                     |   |        | -        |   |                |   | -        |               |   |   | (217,205 | ) |
|        Imputed interest                                                              |   |        | 22,936   |   |                |   | 25,347   |               |   |   | 252,427 |   |
|     Changes in operating assets and liabilities                                                     |   |        |     |   |                |   |     |               |   |   |   |   |
|     Decrease (increase) in:                                                                         |   |        |     |   |                |   |     |               |   |   |   |   |
|        Other receivables and prepaid expenses                                        |   |        | 978      |   |                |   | 662      |               |   |   | (21,105 | ) |
|     (Decrease) increase in:                                                                         |   |        |     |   |                |   |     |               |   |   |   |   |
|        Other payables and accrued expenses                                           |   |        | 20,592   |   |                |   | (6,477   | )                  |   |   | 59,237 |   |
|        Net cash used in operating activities                                         |   |        | (604,969 | )      |                |   | (609,835 | )                  |   |   | (3,263,775 | ) |
|                                                                                                                    |   |        |     |   |                |   |     |               |   |   |   |   |
| CASH FLOWS FROM INVESTING ACTIVITIES                                                                                    |   |        |     |   |                |   |     |               |   |   |   |   |
|     Purchase of property and equipment                                                              |   |        | (8,166   | )      |                |   | (59,410  | )                  |   |   | (455,107 | ) |
|        Decrease (increase) in deposit for purchase of property and equipment              |   |        | 562      |   |                |   | 8,023    |               |   |   | (1,140 | ) |
|        Net cash used in investing activities                                         |   |        | (7,604   | )      |                |   | (51,387  | )                  |   |   | (456,247 | ) |
|                                                                                                                    |   |        |     |   |                |   |     |               |   |   |   |   |
| CASH FLOWS FROM FINANCING ACTIVITIES                                                                                    |   |        |     |   |                |   |     |               |   |   |   |   |
|     Stock issued to founders                                                                        |   |        | -        |   |                |   | -        |               |   |   | 505 |   |
|     Proceeds from issuance of shares                                                                |   |        | -        |   |                |   | -        |               |   |   | 478,300 |   |
|     Contribution by stockholders                                                                    |   |        | -        |   |                |   | -        |               |   |   | 519,157 |   |
|     Distributed to stockholders                                                                     |   |        | -        |   |                |   | -        |               |   |   | (31,409 | ) |
|     Due to a stockholder                                                                            |   |        | 82,142   |   |                |   | 120,472  |               |   |   | 349,911 |   |
|     Due to directors                                                                                |   |        | (62,450  | )      |                |   | (60,314  | )                  |   |   | 455,574 |   |
|     Due to related parties                                                                          |   |        | 591,492  |   |                |   | 570,868  |               |   |   | 2,266,916 |   |
|        Net cash provided by financing activities                                     |   |        | 611,184  |   |                |   | 631,026  |               |   |   | 4,038,954 |   |
|                                                                                                                    |   |        |     |   |                |   |     |               |   |   |   |   |
| EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS                                                            |   |        | 677      |   |                |   | 507      |               |   |   | (270,552 | ) |
|                                                                                                                    |   |        |     |   |                |   |     |               |   |   |   |   |
| NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS                                                                    |   |        | (712     | )      |                |   | (29,689  | )                  |   |   | 48,380 |   |
|                                                                                                                    |   |        |     |   |                |   |     |               |   |   |   |   |
| CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR                                                                          |   |        | 49,092   |   |                |   | 78,781   |               |   |   | - |   |
|                                                                                                                    |   |        |     |   |                |   |     |               |   |   |   |   |
| CASH AND CASH EQUIVALENTS AT END OF YEAR                                                                                |   | $           | 48,380   |   |                | $      | 49,092   |               |   | $ | 48,380 |   |

----

|   |
|--------|

| 1.   | SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION |
|----------------|-------------------------------------------------------------|

| (A)   | Organization |
|-----------------|--------------|

|   | (1) | The balance sheet consisting of the net assets of the acquirer at historical cost and the net assets of the acquiree at historical cost. |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------|

|   | (2) | The statement of operations including the operations of the acquirer for the periods presented and the operations of the acquiree from the date of the transaction. |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (B)   | Principles of consolidation |
|-----------------|-----------------------------|

| (C)   | Use of estimates |
|-----------------|------------------|

| (D)   | Cash and cash equivalents |
|-----------------|---------------------------|

| (E)   | Property and equipment |
|-----------------|------------------------|

| (F)   | Long-lived assets |
|-----------------|-------------------|

| (G)   | Fair value of financial instruments |
|-----------------|-------------------------------------|

| (H)   | Government grant |
|-----------------|------------------|

----

| (I)   | Income taxes |
|-----------------|--------------|

| (J)   | Research and development |
|-----------------|--------------------------|

| (K)   | Foreign currency translation |
|-----------------|------------------------------|

|                                                                                                               | October 31,2013          |   | October 31, 2012         |
|--------------------------------------------------------------------------------------------------------------------|--------------------------|--------|--------------------------|
| Balance sheet items, except for share capital, additional paid-in capital and accumulated deficits, as of year end | US$1=HK$7.7530=RMB6.0943 |   | US$1=HK$7.7494=RMB6.2372 |
| Amounts included in the statements of operations and cash flows for the year                                       | US$1=HK$7.7561=RMB6.1717 |   | US$1=HK$7.7615=RMB6.3283 |

| (L)   | Other comprehensive loss |
|-----------------|--------------------------|

----

| (M)   | Loss per share |
|-----------------|----------------|

| (N)   | Segments |
|-----------------|----------|

| (O)   | Recent Accounting Pronouncements |
|-----------------|----------------------------------|

| 2.   | PROPERTY AND EQUIPMENT |
|----------------|------------------------|

|                           |   | October 31, |    |
|--------------------------------|--------|-------------|---------|
|                           |   | 2013        |    |   | 2012 |   |
|                           |   |        |    |   |   |   |
| Plant and machinery            |   | $           | 266,931 |   |   | $ | 255,836 |   |
| Motor vehicles                 |   |        | 45,239  |   |   |   | 44,202 |   |
| Office equipment               |   |        | 31,824  |   |   |   | 28,153 |   |
| Computer software              |   |        | 5,017   |   |   |   | 5,017 |   |
| Office improvements            |   |        | 131,829 |   |   |   | 128,809 |   |
|                           |   |        | 480,840 |   |   |   | 462,017 |   |
| Less: accumulated depreciation |   |        | 354,272 |   |   |   | 320,404 |   |
|                           |   |        |    |   |   |   |   |   |
| Property and equipment, net    |   | $           | 126,568 |   |   | $ | 141,613 |   |

| 3.   | OTHER PAYABLES AND ACCRUED EXPENSES |
|----------------|-------------------------------------|

|             |   | October 31, |   |
|------------------|--------|-------------|--------|
|             |   | 2013        |   |   | 2012 |   |
|             |   |        |   |   |   |   |
| Other payables   |   | $           | 790    |   |   | $ | 357 |   |
| Accrued expenses |   |        | 58,447 |   |   |   | 37,851 |   |
|   Total     |   | $           | 59,237 |   |   | $ | 38,208 |   |

| 4.   | RELATED PARTY TRANSACTIONS |
|----------------|----------------------------|

----

| 5.   | STOCKHOLDERS’ DEFICIT |
|----------------|-----------------------------|

| 6.   | COMMITMENTS AND CONTINGENCIES |
|----------------|-------------------------------|

| (A)   | Employee benefits |
|-----------------|-------------------|

| (B)   | Lease commitments |
|-----------------|-------------------|

| 2014  |   | $      | 37,947 |   |
|-------|--------|--------|--------|--------|
| 2015  |   |   | 1,116  |   |
| Total |   | $      | 39,063 |   |

----

| (C)   | Capital commitments |
|-----------------|---------------------|

| (D)   | Legal proceedings |
|-----------------|-------------------|

| 7.   | INCOME TAX |
|----------------|------------|

| 8.   | CONCENTRATIONS AND RISKS |
|----------------|--------------------------|

| 9.   | GOING CONCERN |
|----------------|---------------|

----

| 10.   | SUBSEQUENT EVENTS |
|-----------------|-------------------|

----

----

| Name and Address |   | Age |   | Position(s)                                  |
|------------------|--------|-----|--------|----------------------------------------------|
| Chi Ming YU      |   | 40  |   | President, Director                          |
| WANG Hui         |   | 44  |   | Chief Executive Officer, Director            |
| Kai GUI          |   | 44  |   | Director, Secretary, Chief Financial Officer |

|   | 1. | Any petition under the Federal bankruptcy laws or any state insolvency law being filed by or against, or a receiver, fiscal agent or similar officer being appointed by a court for the business or property of such person, or any partnership in which he was a general partner at or within two years before the time of such filing, or any corporation or business association of which he was an executive officer at or within two years before the time of such filing; |
|--------|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 2. | Conviction in a criminal proceeding, or being a named subject of a pending criminal proceeding (excluding traffic violations and other minor offenses);   |
|--------|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|--------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   | 3.     | Being the subject of any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently or temporarily enjoining him from, or otherwise limiting, the following activities:                                                                                                                                                                                                                                                                                                                                                                                        |
|   |   | i.       Acting as a futures commission merchant, introducing broker, commodity trading advisor, commodity pool operator, floor broker, leverage transaction merchant, any other person regulated by the Commodity Futures Trading Commission, or an associated person of any of the foregoing, or as an investment adviser, underwriter, broker or dealer in securities, or as an affiliated person, director or employee of any investment company, bank, savings and loan association or insurance company, or engaging in or continuing any conduct or practice in connection with such activity;  |
|   |   | ii.      Engaging in any type of business practice; or                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|   |   | iii.      Engaging in any activity in connection with the purchase or sale of any security or  commodity or in connection with any violation of Federal or State securities laws or Federal commodities laws;                                                                                                                                                                                                                                                                                                                                                                                          |
|   |   |
|   | 4.     | Being the subject of any order, judgment or decree, not subsequently reversed, suspended or vacated, of any Federal or State authority barring, suspending or otherwise limiting for more than 60 days the right of such person to engage in any activity described in paragraph (3)(i) of this section, or to be associated with persons engaged in any such activity;                                                                                                                                                                                                                                                              |
|   | 5.     | Being found by a court of competent jurisdiction in a civil action or by the Securities and Exchange Commission to have violated any Federal or State securities law, and the judgment in such civil action or finding by the Commission has not been subsequently reversed, suspended, or vacated;                                                                                                                                                                                                                                                                                                                                  |
|   | 6.     | Being found by a court of competent jurisdiction in a civil action or by the Commodity Futures Trading Commission to have violated any Federal commodities law, and the judgment in such civil action or finding by the Commodity Futures Trading Commission has not been subsequently reversed, suspended or vacated;                                                                                                                                                                                                                                                                                                               |
|   | 7.     | Being the subject of, or a party to, any Federal or State judicial or administrative order, judgment, decree, or finding, not subsequently reversed, suspended or vacated, relating to an alleged violation of:                                                                                                                                                                                                                                                                                                                                                                                                                      |
|   |   | i.        Any Federal or State securities or commodities law or regulation; or                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|   |   | ii.       Any law or regulation respecting financial institutions or insurance companies  including, but not limited to, a temporary or permanent injunction, order of disgorgement or restitution, civil money penalty or temporary or permanent cease-and-desist order, or removal or prohibition order; or                                                                                                                                                                                                                                                                                |
|   |   | iii.      Any law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity; or                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|   | 8.     | Being the subject of, or a party to, any sanction or order, not subsequently reversed, suspended or vacated, of any self-regulatory organization (as defined in Section 3(a)(26) of the Exchange Act (15 U.S.C. 78c(a)(26))), any registered entity (as defined in Section 1(a)(29) of the Commodity Exchange Act (7 U.S.C. 1(a)(29))), or any equivalent exchange, association, entity or organization that has disciplinary authority over its members or persons associated with a member.                                                                                                                                        |

----

----

| Executive Officer Compensation Table |   |
|--------------------------------------|--------|
|                                 |   | Fees |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|                                 |   | Earned |   |   |   |   |   |   |   |   |   |   |   | Nonqualified |   |   |   |   |   |   |   |
|                                 |   | or |   |   |   |   |   |   |   |   | Non-Equity |   |   | Deferred |   |   |   |   |   |   |   |
|                                 |   | Paid in |   |   | Stock |   |   | Option |   |   | Incentive Plan |   |   | Compensation |   |   | All Other |   |   |   |   |
|                                 |   | Cash |   |   | Awards |   |   | Awards |   |   | Compensation |   |   | Earnings |   |   | Compensation |   |   | Total |   |
| Name                            |   | (US$) |   |   | (US$) |   |   | (US$) |   |   | (US$) |   |   | (US$) |   |   | (US$) |   |   | (US$) |   |
| (a)                             |   | (b) |   |   | (c) |   |   | (d) |   |   | (e) |   |   | (f) |   |   | (g) |   |   | (h) |   |
|                                 |   |
| WANG Hui                             |   | $ | 43,217 |   |   |   | 0 |   |   |   | 0 |   |   |   | 0 |   |   |   | 0 |   |   |   | 0 |   |   |  $ | 43,217 |   |
| Chi Ming YU                          |   |   | 0 |   |   |   | 0 |   |   |   | 0 |   |   |   | 0 |   |   |   | 0 |   |   |   | 0 |   |   |   | 0 |   |
| Kai GUI                         |   |   | 0 |   |   |   | 0 |   |   |   | 0 |   |   |   | 0 |   |   |   | 0 |   |   |   | 0 |   |   |   | 0 |   |

| Director Compensation |
|-----------------------|
|                  |   | Fees |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|                  |   | Earned |   |   |   |   |   |   |   |   |   |   | Nonqualified |   |   |   |   |   |
|                  |   | or |   |   |   |   |   |   |   | Non-Equity |   |   | Deferred |   |   |   |   |   |
|                  |   | Paid in |   | Stock |   |   | Option |   |   | Incentive Plan |   |   | Compensation |   |   | All Other |   |   |
|                  |   | Cash |   | Awards |   |   | Awards |   |   | Compensation |   |   | Earnings |   |   | Compensation |   | Total |
| Name             |   | (US$) |   | (US$) |   |   | (US$) |   |   | (US$) |   |   | (US$) |   |   | (US$) |   | (US$) |
| (a)              |   | (b) |   | (c) |   |   | (d) |   |   | (e) |   |   | (f) |   |   | (g) |   | (h) |
|                  |
| WANG Hui              |   | 0 |   |   | 0 |   |   |   | 0 |   |   |   | 0 |   |   |   | 0 |   |   |   | 0 |   | 0 |
| Chi Ming YU           |   | 0 |   |   | 106,500 |   |   |   | 0 |   |   |   | 0 |   |   |   | 0 |   |   |   | 0 |   | 106,500 |
| Kai GUI          |   | 0 |   |   | 106,500 |   |   |   | 0 |   |   |   | 0 |   |   |   | 0 |   |   |   | 0 |   | 106,500 |

----

| (1) Title of Class           |   | (2) Name and address of beneficial owner                                                                                |   | (3) Amount and nature of beneficial ownership |       |   | (4) Percent of class |   |
|------------------------------|--------|-------------------------------------------------------------------------------------------------------------------------|--------|-----------------------------------------------|------------|--------|----------------------|--------|
| Common Stock                 |   | WANG Hui, CEO & Director                                                                                            |   |                                          | 22,153,540 |   |                 |   | 38.951 | % |
| Common Stock                 |   | Chi Ming YU, President & Director                                                                                   |   |                                          | 150,000    |   |                 |   | 0.264 | % |
| Common Stock                 |   | Kai GUI, Secretary & Director                                                                                       |   |                                          | 300,000    |   |                 |   | 0.527 | % |
| Common Stock                 |   | Titan Technology Development, LTD.,Room 1903 Hing Yip, Commercial Centre, 272 Des Voeux Road Central, Hong Kong, 718332 |   |                                          | 20,210,960 |   |                 |   | 35.536 | % |
| Common Stock                 |   | WU Ai Ping, Room 802, 35 Weicheng Street, Hongyun Garden, Zhongtangshi Lane, Huangpu Road, Tianhe, Guangzhou, 510655    |   |                                          | 5,000,000  |   |                 |   | 8.791 | % |
| All Officers & Directors |   |                                                                                                                    |   |                                          | 22,603,540 |   |                 |   | 39.742 | % |

----

| 2013    |   | $ | 33,400 |   |  Baker Tilly Hong Kong Limited |
|------------------------|--------|---|--------|--------|-------------------------------------|
| 2012         |   | $ | 33,400 |   |  Baker Tilly Hong Kong Limited |

----

|    |   |                                                                                                                                             |   | Incorporated by reference |   |   |     |   |   |   |   |
|---------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------|--------|---------------------------|--------|--------|----------|--------|--------|--------|--------|
| Exhibit |   | Document Description                                                                                                                             |   | Form                      |   | Date   |     |   | Number |   |   | Filed herewith |   |
|    |   |                                                                                                                                             |   |                      |   |   |     |   |   |   |   |   |   |
| 3.1     |   | Articles of Incorporation                                                                                                                        |   | SB-2                      |   |   | 01-16-07 |   |   |   | 3.1    |   |   |   |   |
| 3.2     |   | Bylaws                                                                                                                                           |   | SB-2                      |   |   | 01-16-07 |   |   |   | 3.2    |   |   |   |   |
| 4.1     |   | Specimen Stock Certificate                                                                                                                       |   | SB-2                      |   |   | 01-16-07 |   |   |   | 4.1    |   |   |   |   |
| 14.1    |   | Code of Ethics                                                                                                                                   |   |                      |   |   |     |   |   |   |   |   |   |   | X |   |
| 10.1    |   | Titan – ABMT Loan Agreement                                                                                                                |   |                      |   |   |     |   |   |   |   |   |   |   | X |   |
| 31.1    |   | Certification of Chief Executive Officer pursuant to 15d-15(e), promulgated under the Securities and Exchange Act of 1934, as amended.           |   |                      |   |   |     |   |   |   |   |   |   |   | X |   |
| 31.2    |   | Certification of Chief Financial Officer pursuant to 15d-15(e), promulgated under the Securities and Exchange Act of 1934, as amended.           |   |                      |   |   |     |   |   |   |   |   |   |   | X |   |
| 32.1    |   | Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Chief Executive Officer) |   |                      |   |   |     |   |   |   |   |   |   |   | X |   |
| 32.2    |   | Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Chief Financial Officer) |   |                      |   |   |     |   |   |   |   |   |   |   | X |   |
| 99.1    |   | Audit Committee Charter                                                                                                                          |   |                      |   |   |     |   |   |   |   |   |   |   | X |   |
| 99.2    |   | Disclosure Committee Charter                                                                                                                     |   |                      |   |   |     |   |   |   |   |   |   |   | X |   |

----

| Signature      |   | Title                                           |   | Date              |
|----------------|--------|-------------------------------------------------|--------|-------------------|
|           |   |                                            |   |              |
| /s/Chi Ming YU |   | President and Director                          |   | February 13, 2014 |
| Chi Ming YU    |   | (Principal Executive Officer)                   |   |              |
|           |   |                                            |   |              |
| /s/Kai GUI     |   | Director, Secretary and Chief Financial Officer |   | February 13, 2014 |
| Kai GUI        |   | (Principal Financial Officer)                   |   |              |
|           |   |                                            |   |              |
| /s/WANG Hui    |   | Director and Chief Executive Officer            |   | February 13, 2014 |
| WANG Hui       |   | (Controller)                                    |   |              |

----